Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPXP01
- Development stage
- Preclinical
- Lead developer
- Genovyn
- Modality
- Small Molecules
01
Overview
NPXP01 is a preclinical-stage small molecule drug candidate being developed by Genovyn (under its Panovyn subsidiary) for the treatment of pancreatic cancer. The therapeutic operates via an ATP-linked mechanism of action, aiming to bypass conventional pathways and directly target the biological barriers of aggressive pancreatic tumors.
Beyond the preview
Go deeper on NPXP01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NPXP01.